Loading
In a clinical trial the experimental drug is free to the patient and the payer, and since 2022 Medicaid must cover routine trial costs like Medicare and private plans do; pointing more patients to trials lowers bills as well as advancing science.
Fewer than one in ten adults with cancer join a trial, and cost concerns about routine care coverage are a documented barrier. The Clinical Treatment Act (effective January 2022) requires state Medicaid programmes to cover routine costs in qualifying trials, joining Medicare (since 2000) and Affordable Care Act plans. With the sponsor supplying the drug, a trial arm is often the cheapest way to receive a new therapy. Systematic trial matching at diagnosis, and payer navigators who present trials alongside coverage options, would turn a research goal into a cost tool.
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly, National Cancer Institute (NIH).
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly, National Cancer Institute (NIH).
Shares AI trial matching & clinical decision support, Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly, National Cancer Institute (NIH).
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly, National Cancer Institute (NIH).
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly, National Cancer Institute (NIH).
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly, National Cancer Institute (NIH).
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly.